Pharsight

Drugs that contain Lefamulin Acetate

1. Xenleta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8153689 NABRIVA Pleuromutilin derivatives for the treatment of diseases mediated by microbes
Mar, 2028

(4 years from now)

US8071643 NABRIVA Pleuromutilin derivatives for the treatment of diseases mediated by microbes
Jan, 2029

(4 years from now)

US9120727 NABRIVA Process for the preparation of pleuromutilins
May, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 19, 2024
Generating Antibiotic Incentives Now (GAIN) Aug 19, 2029

NCE-1 date: 2028-08-19

Market Authorisation Date: 19 August, 2019

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

XENLETA family patents

Family Patents